BioPharmSignal logoBioPharmSignal

Biotech News

CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

CRISPR Therapeutics (CRSP)CRISPR TherapeuticsConference / presentation

ZUG, Switzerland and BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:05 p.m. EST.

Related news

SRPTSarepta Therapeutics2026-08-31 20:30 EST

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

NTLAIntellia2026-09-04 12:00 EST

Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference

CRSPCRISPR Therapeutics2026-08-28 14:31 EST

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

CRSPCRISPR Therapeutics2026-11-04 14:01 EST

CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition

KRYSKrystal Biotech2026-09-03 12:00 EST

Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference

RCKTRocket Pharmaceuticals2026-10-15 11:00 EST

Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference

SANASana Biotechnology2026-09-01 20:05 EST

Sana Biotechnology to Present at September 2026 Investor Conferences

CRBUCaribou2026-11-04 14:00 EST

Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting

NTLAIntellia2026-10-29 12:00 EST

Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026

VYGRVoyager Therapeutics2026-10-27 12:01 EST

Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026

View all latest news

CRISPR Therapeutics

Gene-Based Medicine Platform CRISPR Therapeutics develops gene-edited medicines across hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare disease. Its toolkit includes CRISPR/Cas9, the SyNTase editing platform, lipid-nanoparticle delivery and engineered cell therapies. CASGEVY CASGEVY...

Recent company news

CRSPCRISPR Therapeutics2026-11-04 14:01 EST

CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition

CRSPCRISPR Therapeutics2026-11-02 21:01 EST

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

CRSPCRISPR Therapeutics2026-11-02 13:00 EST

CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer

CRSPCRISPR Therapeutics2026-10-19 20:05 EST

CRISPR Therapeutics Announces Chief Financial Officer Transition

CRSPCRISPR Therapeutics2026-10-08 12:30 EST

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026

Stock data

Close
48.56 USD
Market cap
5.02B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States